Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Biospecimen Reporting for Improved Study Quality.

Moore HM, Kelly A, Jewell SD, McShane LM, Clark DP, Greenspan R, Hainaut P, Hayes DF, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J.

Biopreserv Biobank. 2011 Apr;9(1):57-70.

2.

Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx.

Huber GF, Züllig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ.

BMC Cancer. 2011 Jun 3;11:217:1-8. doi: 10.1186/1471-2407-11-217.

3.

Biomarker studies: a call for a comprehensive biomarker study registry.

Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L.

Nat Rev Clin Oncol. 2011 Mar;8(3):171-6. doi: 10.1038/nrclinonc.2011.4. Review.

PMID:
21364690
4.

New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies.

Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JP.

Pancreas. 2011 May;40(4):522-32. doi: 10.1097/MPA.0b013e31820bf8ac.

PMID:
21343832
5.

Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease.

Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, Abrams KR, Moreno S, McAllister KS, Palmer S, Kaski JC, Timmis AD, Hingorani AD.

PLoS Med. 2010 Jun 1;7(6):e1000286. doi: 10.1371/journal.pmed.1000286. Review.

6.

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG.

BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. No abstract available.

7.

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Schulz KF, Altman DG, Moher D; CONSORT Group.

BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332. No abstract available.

8.

Increased shedding of HU177 correlates with worse prognosis in primary melanoma.

Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I.

J Transl Med. 2010 Feb 23;8:19. doi: 10.1186/1479-5876-8-19.

9.

Randomized clinical trials with biomarkers: design issues.

Freidlin B, McShane LM, Korn EL.

J Natl Cancer Inst. 2010 Feb 3;102(3):152-60. doi: 10.1093/jnci/djp477. Epub 2010 Jan 14.

10.

Competing risks and time-dependent covariates.

Cortese G, Andersen PK.

Biom J. 2010 Feb;52(1):138-58. doi: 10.1002/bimj.200900076.

PMID:
20029852
11.

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Mallett S, Timmer A, Sauerbrei W, Altman DG.

Br J Cancer. 2010 Jan 5;102(1):173-80. doi: 10.1038/sj.bjc.6605462. Epub 2009 Dec 8. Review.

12.

Assessment of claims of improved prediction beyond the Framingham risk score.

Tzoulaki I, Liberopoulos G, Ioannidis JP.

JAMA. 2009 Dec 2;302(21):2345-52. doi: 10.1001/jama.2009.1757. Review.

PMID:
19952321
13.

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stål O, Linn S, Landberg G.

J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9. doi: 10.1093/jnci/djp412. Epub . Erratum in: J Natl Cancer Inst. 2010 Feb 3;102(3):208.

14.

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT.

J Clin Oncol. 2009 Nov 20;27(33):5519-28. doi: 10.1200/JCO.2008.21.6283. Epub 2009 Oct 26.

15.

CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.

Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Höfler H, Keller G.

Eur J Cancer. 2009 Dec;45(18):3326-35. doi: 10.1016/j.ejca.2009.09.021. Epub 2009 Oct 12.

PMID:
19822419
16.

Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Simon RM, Paik S, Hayes DF.

J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.

17.

Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E.

Breast Cancer Res. 2009;11(5):R67. doi: 10.1186/bcr2359. Epub .

18.

MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections.

Djidja MC, Claude E, Snel MF, Scriven P, Francese S, Carolan V, Clench MR.

J Proteome Res. 2009 Oct;8(10):4876-84. doi: 10.1021/pr900522m.

PMID:
19673544
19.

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.

20.

Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer.

Vormittag L, Gleiss A, Scheithauer W, Lang F, Laengle F, Kornek GV.

Oncology. 2009;77(2):140-6. doi: 10.1159/000229754. Epub 2009 Jul 23.

PMID:
19628952
Items per page

Supplemental Content

Write to the Help Desk